U · A
Unknown Author
January 24, 2026
Kirkland Represents CICC on Fosun New Medicine’s Privatization of Shanghai Henlius
1 min
AI-made summary
- Kirkland & Ellis is advising China International Capital Corporation Hong Kong Securities Limited, the financial adviser to Shanghai Fosun New Medicine Research Company Limited, on the proposed privatization of Shanghai Henlius Biotech, Inc
- The privatization will be carried out through a merger by absorption and was announced on June 24, 2024
- The Kirkland team is led by corporate partners Joey Chau and Nelson Ni, with support from debt finance partners Jacqueline Zheng and Sean Zhang.
Kirkland & Ellis is advising China International Capital Corporation Hong Kong Securities Limited, financial adviser to Shanghai Fosun New Medicine Research Company Limited, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKSE: 2196), on the proposed privatization of Shanghai Henlius Biotech, Inc. (HKSE: 2696). The privatization, which will be implemented by way of merger by absorption, was announced on June 24, 2024. Read Fosun Pharma and Henlius' joint announcement
The Kirkland team is led by corporate partners Joey Chau and Nelson Ni, with assistance from debt finance partners Jacqueline Zheng and Sean Zhang.
U
Article Author
Unknown Author
The Sponsor